The Role of the Antidepressants in Managing Chemotherapy-Induced Neuropathic Pain: A Systematic Review.
Rosamaria Caminiti, Valeria Mazza, Saverio Nucera et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed the efficacy and safety of antidepressants, particularly duloxetine and amitriptyline, in managing chemotherapy-induced peripheral neuropathy (CIPN) pain in adults. The review included 11 studies and found that duloxetine led to clinically meaningful reductions in neuropathic pain, while evidence for amitriptyline was limited. Overall, antidepressants were well tolerated.
Key findings
- Duloxetine showed clinically meaningful reductions in neuropathic pain as assessed by VAS, NRS, and CTCAE measures.
- Topical amitriptyline demonstrated promising analgesic effects, though evidence is limited.
- Combination therapies with duloxetine and other agents were associated with additional pain intensity reductions.
- Antidepressant therapy was generally well tolerated with predominantly mild adverse events.
Why it matters
Chemotherapy-induced peripheral neuropathy can significantly impair quality of life for cancer patients. Understanding the role of antidepressants in managing this condition can help clinicians optimize pain management strategies and improve patient outcomes.